Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629065 · ClinicalTrials.gov registry record · NA
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
A NA study of Breast Cancer and Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT05629065 is a NA study of Breast Cancer and Gynecologic Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 800 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05629065, a NA study of Breast Cancer and Gynecologic Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to increase serious illness conversations (SICs) about patients goals and preferences regarding their healthcare between patients with cancer and their oncology clinicians and improved care provided near the end of life.
Conditions Studied
Interventions
- OTHER Clinician Nudge Email
- OTHER Patient Nudge Letter and Share questionaire
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2028-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05629065
The ClinicalTrials.gov registry entry for NCT05629065 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Clinician Nudge Email is the first listed.
NCT05629065 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05629065 about?
NCT05629065 is a clinical study titled "Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)". The purpose of this study is to increase serious illness conversations (SICs) about patients goals and preferences regarding their healthcare between patients with cancer and their oncology clinicians and improved care provided near the end of life.
What is the current status of trial NCT05629065?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2022-11-28. Estimated completion is 2028-06.
What conditions does trial NCT05629065 study?
This clinical trial studies the following conditions: Breast Cancer, Gynecologic Cancer, Gastrointestinal Cancer, Thoracic Cancer, Genitourinary Cancer.
What interventions are being tested in trial NCT05629065?
The interventions under investigation include: Clinician Nudge Email (OTHER), Patient Nudge Letter and Share questionaire (OTHER).
Who is sponsoring clinical trial NCT05629065?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05629065 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.